{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"29.480","rs_stock_flag":false,"fiscal_year_end":"","hist_closedate":"","replication_method":null,"amt_os":"136,218,830","primaryexch":"香港交易所","ric":"3378.HK","product_subtype":null,"db_updatetime":"2025年12月23日09:36","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":null,"inline_upper_strike_price":"","sedol":"BW9DKD6","am":"121.89","iv":"","ew_strike":"","as":"24.360","geographic_focus":null,"incorpin":"中華人民共和國","etp_baseCur":null,"ew_amt_os":"","bd":"24.340","registrar":"卓佳證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"100","update_time":"2025-12-23 01:36:34.0","lo52":"","shares_issued_date":"2025年12月23日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"張發明","underlying_ric":"3378.HK","hi52":"","issuer_name":"翰思艾泰生物醫藥科技（武漢）股份有限公司 - B - H股","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年12月23日10:25","aum_date":"","lo":"23.000","mkt_cap":"3.31","f_aum_hkd":null,"ew_sub_per_to":"","ls":"24.360","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"0","aum":"","issued_shares_class_B":null,"vo":"4.10","secondary_listing_flag":false,"listing_date":"2025年12月23日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"翰思艾泰生物醫藥科技（武漢）股份有限公司 - B - H股","nm_s":"翰思艾泰－Ｂ","sym":"3378","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.020","strike_price":"","summary":"翰思艾泰生物醫藥科技（武漢）股份有限公司是一家主要從事腫瘤免疫療法發現、開發及商業化的中國公司。該公司產品管線主要包括HX009、HX30和 HX044等針對腫瘤學的臨床階段候選藥物、以及針對自身免疫和腫瘤市場的抗體偶聯藥物、雙特異性抗體及單克隆抗體等臨床前階段候選藥物。該公司核心產品HX009是一種自主研發的抗程序性死亡受体1（PD-1）和信号调节蛋白α（SIRPα）雙功能抗體融合蛋白。HX301是一種多靶點激酶抑制劑。HX044是雙功能抗细胞毒性T淋巴细胞相关抗原4（CTLA-4）抗體SIRPα融合蛋白。該公司還運營抗體技術平台VersatiBody以及自身免疫疾病治療平台autoRx40。該公司主要在國内市場開展業務。","op":"28.900","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"中國湖北省武漢市<br/>東湖新技術開發區<br/>九峰一路1號<br/>生物創新園二期A8棟","pc":"0.00","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":null,"hdr":false,"launch_date":"","hc":"","isin":"CNE100007C34","moneyness":""}},"qid":"1766457640674"}
